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ABSTRACT 24 
Current treatments for African trypanosomiasis are either toxic, costly, difficult to 25 
administer or prone to elicit resistance. This study evaluates the activity of 26 
bisnaphthalimidopropyl (BNIP) derivatives against Trypanosoma brucei. BNIPDabut, the 27 
most active compound, showed in vitro inhibition in the single unit nanomolar range, 28 
similar to the reference drug pentamidine, and presented low toxicity and adequate 29 
metabolic stability. Additionally, using a murine model of acute infection and live imaging, 30 
significant decrease of parasite load in BNIPDabut-treated mice was observed. However, 31 
cure was not achieved. BNIPDabut constitutes a new scaffold for antitrypanosomal drugs 32 
that deserves further consideration.  33 
 3 
 
MAIN TEXT 34 
African trypanosomiasis is an infectious disease caused by parasites of the species 35 
Trypanosoma brucei. The parasite is transmitted by an insect vector, the tsetse fly 36 
(Glossina spp.). The disease is mainly distributed in the African continent, with distinct 37 
subspecies causing different forms of human disease: T. brucei gambiense infection 38 
produces a chronic form that may last for years and was responsible for nearly 98% of the 39 
cases in the past decade; the acute form is caused by T. brucei rhodesiense and usually kills 40 
the host within weeks, accounting for the remaining 2% of the reported cases (1, 2). 41 
Since vaccination remains elusive and vector control strategies are frequently 42 
insufficient, chemotherapy is still the most efficient option to control the disease (2-5). 43 
However, the drugs in use have many drawbacks, mostly related with cost, effectiveness, 44 
toxicity, difficult administration and the appearance of resistance (6). Therefore, the 45 
development of new drugs is urgently needed. 46 
Bisnaphthalimidopropyl (BNIP) derivatives have previously been shown to possess both 47 
anticancer activity (7-11) and also have been shown to be antiparasitic against a related 48 
trypanosomatid Leishmania infantum (12-14). The potential activity of three BNIP 49 
derivatives previously synthetized (10, 11, 15, >96% pure), namely BNIPDiaminobutane 50 
(BNIPDabut), BNIPDiaminoheptane (BNIPDahep) and BNIPDiaminooctane (BNIPDaoct) 51 
(FIG 1A), against T. brucei brucei Lister 427 bloodstream forms (BSF) was investigated. 52 
These were selected from a series of compounds based on preliminary studies of 53 
bioavailability and in vitro and in vivo activity against both T. brucei and L. infantum (12 54 
and unpublished data). The in vitro antiparasitic activity was assessed using a resazurin 55 
assay, as previously described, with minor modifications (incubation with 103 56 
parasites/well, in 200 µL, 16). All three BNIPs demonstrated a potent inhibitory effect on 57 
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the parasites’ growth, with IC50 within the nanomolar range (FIG 1B, TABLE 1). 58 
BNIPDabut was the most active compound with an IC50 ± SD of 2.4 ± 1.0 nM similar to the 59 
reference drug pentamidine with 2.9 ± 0.7 nM (TABLE 1). Since this class of compounds 60 
has previously been described as inhibitors of the L. infantum Silent information regulator 2 61 
related protein 1 (LiSir2rp1, accession: AAN39039.1) (15), we evaluated whether 62 
inhibition of the T. brucei orthologue, TbSir2rp1 (accession: AAX70528.1) would be a 63 
possible mechanism of action. Whereas BNIPDabut was shown to inhibit the NAD+-64 
dependent deacetylase activity of TbSir2rp1with an IC50 ± SD of 155 ± 42 µM, suggesting 65 
that this is not the major mechanism of action (data not shown), LiSir2rp1 was inhibited 66 
with an IC50 ± SD of 35.0 ± 5.8 µM (15). The 47% identity between LiSir2rp1 and 67 
TbSir2rp1 obtained by protein sequence alignment (Clone Manager 9, BLOSUM 62 68 
scoring matrix) might explain the differences observed (17). Moreover, no correlation 69 
between the enzymatic inhibition and activity towards T. brucei parasites was observed. To 70 
evaluate in vitro toxicity towards mammalian cells, all the compounds were studied with 71 
the MTT assay (18) in THP1-derived macrophages and two primary cell cultures: rat 72 
cortical neurons and mouse hepatocytes (TABLE 2). The CC50 values for these molecules 73 
translate into selectivity indexes (SI=CC50/IC50) higher than 100. All BNIP derivatives 74 
exhibited high SIs, with BNIPDabut in particular being at least 800 times more selective 75 
towards T. brucei parasites. All BNIPs had potency and selectivity that warranted 76 
additional characterization (TABLE 2). To further evaluate the potential toxic effects of 77 
BNIPs in host cells, a set of in vitro assays was performed in hepatocytes and neuronal 78 
primary cells. These assays evaluated different possible mechanisms of toxicity based on: 79 
a) reactive oxygen species determination (CM-H2DCFDA probe, by High Content 80 
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Analysis – HCA); b) mitochondrial dysfunction (TMRM probe, by HCA); c) membrane 81 
integrity (lactate dehydrogenase quantification); d) apoptosis (caspase 3/7 activation); e) 82 
either DNA damage for hepatocytes (H2AX antibody, by HCA) or neurite outgrowth for 83 
neurons (anti-tubulin III antibody, by HCA); f) cell viability as measured by WST-8 probe 84 
and g) Hoechst staining for nuclear detection. Nimesulide (400 µM) was included as a 85 
positive control and the vehicle as a neutral control (19-21). The relative percentage of 86 
deviation from the neutral control was quantified and assigned with a number from 0 to 5 87 
according to the following criteria: 0 (0-20% deviation), 1 (20-40%), 2 (40-60%), 3 (60-88 
100%), 4 (100-1000%), or 5 (>1000% deviation). The sum of these values was posteriorly 89 
ranked to create a combined injury criteria that varied from no injury (0), low injury (1 to 90 
<5), moderate injury (≥5-to <12) to high injury (≥ 12). All BNIPs showed a dose-dependent 91 
injury score close to pentamidine in both cell types (FIG 2A-B). BNIPDabut had a toxicity 92 
profile indistinguishable from the reference drug pentamidine. 93 
To infer metabolic stability, mouse microsomes were incubated over 45 minutes 94 
with 5 µM of each compound and the drug was quantified by LC-MS/MS. Similarly to 95 
pentamidine, BNIPDabut was more stable than both BNIPDahep and BNIPDaoct, with 95 96 
to 100% of the drug not being metabolized (TABLE 3). This high metabolic stability is an 97 
indicator that the molecule is not easily subjected to common inactivation or loss of 98 
potency by reactions catalized by liver enzymes, and is kept intact in circulation for longer 99 
periods. 100 
To determine the pharmacokinetics of BNIPDabut, a 10 mg/kg dose was 101 
administered to BALB/c mice by intravenous injection. Five minutes after, a concentration 102 
of 58 nM was achieved and during the following 24 hours remained higher than 41 nM 103 
(data not shown), thus approximately 8 times higher than the calculated IC90. 104 
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Taking in consideration the previous results, BNIPDabut was chosen for in vivo efficacy 105 
studies. All the experiments involving animals were carried out in accordance with the 106 
IBMC Animal Ethics Committees and the Portuguese and European Authorities for Animal 107 
Health guidelines. T. b. brucei Lister 427 parasites were transfected with a construct kindly 108 
provided by M. Taylor, in which the red-shifted luciferase gene (PpyRE9H) is flanked by 109 
5´VSG/3´tubulin (22). Upon transfection, clones were screened for bioluminescent signal 110 
and the ones expressing the highest levels were selected. Their in vitro growth was 111 
compared to wild type parasites and found to be similar (data not shown). In vitro detection 112 
limits were also analyzed for BSF in a 96-well plate and determined to be about 2500 cells 113 
(data not shown). BALB/c female mice were inoculated intraperitoneally with 104 BSF. 114 
Three days post-infection, five groups of mice (n=4) were treated intravenously with: 115 
saline, pentamidine at 2.5 mg/kg/day, DMSO at 16.7%, or BNIPDabut both at a 10 116 
mg/kg/day and a 20 mg/kg/day dose. Pentamidine was administered for 4 days, while 117 
BNIPDabut and the respective vehicle (DMSO 16.7%) were administered for 6 days (FIG 118 
3A). No adverse effects were observable following any administration regimen. Treatment 119 
efficacy was followed through whole animal live imaging using an IVIS Lumina LT 120 
(Perkin Elmer). Parasitaemias were also assessed, and animals were euthanized after 121 
reaching a parasitaemia of 108 parasites/mL. Similarly to pentamidine, two administrations 122 
of BNIPDabut both at 10 and 20 mg/kg efficiently reduced parasitaemia below detection 123 
limit (5x104/mL) (FIG 3B). However, whole mice imaging reveals that reduction of 124 
bioluminescent signal to the background level (obtained with non-infected mice) is only 125 
achieved in mice treated with 20 mg/kg of BNIPDabut during at least 5 consecutive days as 126 
opposed to 2 days treatment for the pentamidine group. Although treatment with 20mg/kg 127 
BNIPDabut apparently cleared the infection, cure was not achieved as the parasite burden 128 
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relapsed when treatment was stopped (FIG 3B). Indeed, BNIPDabut (10 and 20 mg/kg) 129 
treatment increases mice survival, but in contrast with pentamidine, animals were not cured 130 
(FIG 3C). A hypothesis is that BNIPDabut, although highly trypanocidal cannot reach and 131 
clear all parasites, either due to potency, distribution, or both. A frequent observation was 132 
that recurrence of parasitaemia was preceded by imaging of parasite loads in the peritoneal 133 
zone, where animals were originally injected with the parasites. It has been demonstrated 134 
that trypanosomes invade extravascular tissues as a defense mechanism against host 135 
immunity, and that this process may be related with relapses after treatment interruption 136 
(23, 24). Indeed, the presence of parasites in the extravascular tissues might explain the 137 
discrepancy of radiance values between days 4 and 12 while average parasitaemia remain 138 
similar in mice treated with BNIPDabut (10 and 20 mg/kg) (FIG 3C). Nonetheless, it 139 
remains to be elucidated whether BNIPDabut is active on a mouse model of the late stage 140 
of the disease as this is the central objective in drug discovery against human African 141 
trypanosomiasis. Additional chemical modifications to BNIPDabut may improve potency 142 
and/or distribution of the drug, while maintaining or improving the toxicity and metabolism 143 
profile. 144 
 In conclusion, this work demonstrates that BNIPDabut has potent in vitro and in 145 
vivo antitrypanosomal activity with acceptable toxicity and high metabolic stability. 146 
However, chemical modifications are needed in order to improve its pharmacodynamic 147 
and/or pharmacokinetic properties. 148 
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FIG 1 In vitro antitrypanosomal activity of BNIP compounds. 245 
A) Chemical structures of pentamidine and BNIP derivatives BNIPDabut, BNIPDahep, 246 
BNIPDaoct. B) Growth inhibition curves of Trypanosoma brucei brucei BSF incubated in 247 
vitro with the indicated concentrations of pentamidine, BNIPDabut, BNIPDahep or 248 
BNIPDaoct for 72h. Parasite density was evaluated using resazurin. Dots and error bars 249 
represent the mean + standard deviation of antiparasitic activity. Data of 3 independent 250 
experiments. 251 
 252 
FIG 2 In vitro toxicity of BNIP derivatives. 253 
A)  Hepatotoxicity injury score. The score was calculated as the sum of individual scores 254 
obtained from a panel of in vitro cytotoxicity assays that include: measurement of reactive 255 
oxygen species using CM-H2DCFDA and cells imaging by high content analysis; 256 
assessment of mitochondrial dysfunction measured by TMRM probe dynamics in cells and 257 
image by high content analysis; membrane integrity assayed by lactate dehydrogenase 258 
quantification; DNA damage by imaging with H2AX antibody and high content analysis; 259 
and apoptosis by caspase 3/7 activation; Hoechst staining for nuclear detection; and cell 260 
viability by WST-8 probe. Nimesulide (400 µM), an approved drug with a mild 261 
toxicological profile, was included as a toxicity control. Individual scores are calculated 262 
based on the relative percentage of deviation from the negative control quantified and 263 
assigned with a number from 0 to 5 according to the following criteria: 0 (0-20% 264 
deviation), 1 (20-40%), 2 (40-60%), 3 (60-100%), 4 (100-1000%), or 5 (>1000% 265 
deviation). The data represent the mean sum of these values + standard deviation B) 266 
Neurotoxicity Injury Score. The score was calculated similarly to the hepatotoxicity score 267 
but instead of DNA damage by H2AX antibody, an assay to test neurite outgrowth as 268 
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imaged with an anti-tubulin III antibody and high content analysis was performed. The data 269 
represent the mean sum of these values + standard deviation.  Data of 2 independent 270 
experiments. 271 
 272 
FIG 3 BNIPDabut in vivo efficacy against T. b. brucei. 273 
A) Schematic of the experimental design to evaluate the in vivo efficacy of BNIPDabut. B) 274 
Mice were infected with 104 LUC+ BSF by intraperitoneal injection and initiated the 275 
different treatments 3 days post-infection. Whole mice bioluminescence imaging was done 276 
at days 3, 4, 9 and 12 using an IVIS LUMINA LT and upon injection of 2.1mg luciferin. 277 
Bioluminescence average radiance (p/sec/cm2/sr) of whole mice was quantified and the 278 
mean + standard deviation (n=4) is shown in bars. Parasitemia was determined using a 279 
haemocytometer and the mean + standard deviation is represented by red dots. Red crosses 280 
represent the parasitaemia of the only animal where parasites could be detected and 281 
quantified. Parasitaemia detection limit is 5x104 parasites/mL. C) Kaplan-Meyer survival 282 
curves of the infected mice treated with controls and experimental doses of BNIPDabut. B-283 
C) The data is representative of 3 independent experiments. 284 
 285 



TABLE 1 In vitro activity of BNIP derivatives against Trypanosoma 
brucei L427 bloodstream forms 
  IC50 ± SD (nM)  IC90 ± SD (nM)  
Pentamidine  2.94 ± 0.74  5.26 ± 0.58  
BNIPDabut  2.35 ± 0.99  3.83 ± 1.40  
BNIPDahep  14.32 ± 1.21  23.07 ± 1.01  
BNIPDaoct  26.15 ± 10.43  63.36 ± 21.19  
 
TABLE 2 In vitro cytotoxity of BNIP derivatives in different cell types 
 CC50 ± SD (µM) Selectivity Index*
 THP1 Hepatocytes Neurons THP1 Hepatocytes Neurons 
Pentamidine 47.73 ± 3.32 18.21 ± 0.66 8.23 ± 0.88 16259 6203 2803 
BNIPDabut 5.90 ± 0.40 9.19 ± 0.06 2.06 ± 1.69  2514 3916 878  
BNIPDahep 3.34 ± 0.11 4.23 ± 0.48 2.31 ± 1.65  233 295 161  
BNIPDaoct 3.88 ± 0.59 18.35 ± 4.58 3.97 ± 1.30  148 702 152  
*Selectivity Index = CC50 cell line/IC50 T. brucei 
TABLE 3 Mouse microsomal stability 
 Metabolic stability (%)  In vitro Intrinsic Clearance Clint (µL/min/mg protein)  Degradation non NADPH-dependent (%)  
Pentamidine 95 - 100  -  < 5 
BNIPDabut 95 - 100  -  < 5  
BNIPDahep 85  7  < 5  
BNIPDaoct 64  20  9  
 
